The $300M offering is being conducted shortly after strong pipeline catalysts (ASCO data, Roche deal, NDA acceptance), suggesting the company is opportunistically raising capital at a premium to cash value. The immediate dilution pressure is the key near-term risk. Monitor the pricing of the offering relative to the $28.29 close on June 5 — a discount greater than 5% would be particularly bearish. Watch for any insider participation as a mitigating signal.
Price Chart
Executive Summary
IDEAYA Biosciences filed a 424B5 prospectus supplement for a $300M underwritten public offering of common stock and pre-funded warrants, with an additional $45M greenshoe option. The offering comes on the heels of positive Phase 2/3 data for darovasertib in uveal melanoma presented at ASCO on June 1, a newly announced Roche collaboration for IDE892 in pancreatic cancer, and an NDA acceptance for review under the FDA's Real-Time Oncology Review program. The massive dilution (~12%+ at current share count, more with warrants exercised) is the dominant near-term factor, offsetting the positive pipeline catalysts and potentially capping upside.
Key Facts
- $300 million offering of common stock and pre-funded warrants
- Underwriters have option to purchase up to an additional $45 million of common stock
- Last reported stock price: $28.29 on June 5, 2026
- Net tangible book value as of March 31, 2026: $937.3 million, or $10.67 per share
- 87,856,154 shares outstanding as of March 31, 2026
- Proceeds for continued clinical development and potential commercialization of darovasertib for uveal melanoma, advancement of pipeline, and general corporate purposes
- Positive OptimUM-02 Phase 2/3 data presented June 1, 2026: darovasertib combination met primary endpoint with median PFS 6.9 months vs 3.1 months (HR: 0.42; p<0.0001)
- FDA agreed to review NDA for darovasertib under Real-Time Oncology Review program in April 2026; NDA filing expected H2 2026
- Roche clinical collaboration announced June 3, 2026 for IDE892 in MTAP-deleted pancreatic cancer
Financial Impact
$300M offering (plus up to $45M greenshoe) representing approximately 12-17% dilution to existing shareholders at the current ~88M share count, with additional dilution from pre-funded warrants
Risk Factors
- Immediate and substantial dilution to existing shareholders
- Dilution could be 12-17%+ depending on exercise of greenshoe and pre-funded warrants
- Proceeds use is at management's broad discretion with no specific M&A target identified
- Biotech market volatility may amplify the share price impact of a large secondary
- Pre-funded warrants have no public trading market and limited liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-261756 |
| Document: 0001193125-26-261756-index-headers.html | 0001193125-26-261756 |
| Document: 0001193125-26-261756-index.html | 0001193125-26-261756 |
| Document: 0001193125-26-261756.txt | 0001193125-26-261756 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $36.11 $39.95 | ▲ +10.63% | ▲ +11.87% | $37.05 (+2.60%) |
Jun 23, 2026 14w ago | 8-K | $36.28 $35.00 | ▼ −3.53% | ▼ −5.46% | $37.05 (+2.12%) |
Jun 10, 2026 16w ago | 8-K | $28.84 $37.28 | ▼ −29.26% | ▼ −27.37% | $37.05 (−28.47%) |
Jun 9, 2026 16w ago | 424B5 | $27.60 $37.28 | ▼ −35.07% | ▼ −31.45% | $37.05 (−34.24%) |
Jun 8, 2026 16w ago | 424B5 | $28.07 $40.51 | ▼ −44.32% | ▼ −42.87% | $37.05 (−31.99%) |
Jun 3, 2026 17w ago | 8-K | $28.40 $37.65 | ▲ +32.57% | ▲ +33.57% | $37.05 (+30.46%) |
May 5, 2026 21w ago | 8-K | $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $37.05 (+28.91%) |
May 5, 2026 21w ago | 424B5 | $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $37.05 (+28.91%) |
Apr 13, 2026 24w ago | 8-K | $32.82 $28.13 | ▼ −14.29% | ▼ −22.02% | $37.05 (+12.89%) |
Apr 9, 2026 25w ago | 8-K | $31.00 $28.74 | ▼ −7.29% | ▼ −14.86% | $37.05 (+19.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access